Base de dados : HANSEN
Pesquisa : HANSENIASE DIMORFA/QUIMIOTER [Descritor de assunto]
Referências encontradas : 48 [refinar]
Mostrando: 1 .. 20   no formato [Detalhado]

página 1 de 3 ir para página          

  1 / 48 HANSEN  
              next record last record
seleciona
para imprimir
Id:27315
Autor:Ganapati, R; Pai, V. V; Shroff, H. J; Gandewar, Kailas.
Título:Rate of decline in bacterial index in leprosy; observations after three different chemotherapeutic interventions.
Fonte:Int. J. Lepr;65(2):264-266, Jun. 1997. tab, graf.
Descritores:Hanseníase Dimorfa/quimioter
Hanseníase Dimorfa/microbiol
Hanseníase Virchowiana/quimioter
Hanseníase Virchowiana/microbiol
Rifampina/uso terap
Ofloxacino/uso terap
Localização:BR191.1


  2 / 48 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:27314
Autor:Pavithran, K; Satish, T. C.
Título:Dapsone-induced motor polyneuropathy in a patient with leprosy.
Fonte:Int. J. Lepr;65(2):262-263, Jun. 1997. .
Descritores:Hanseníase Dimorfa/quimioter
Dapsona/ef adv
Dapsona/uso terap
Doença dos Neurônios Motores/ind quim
Doença dos Neurônios Motores/diag
Limites:Humanos
Masculino
Feminino
Localização:BR191.1


  3 / 48 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:27280
Autor:Chaudhury, Sachin; Hajra, Sunil Kumar; Mukerjee, Ashutosh; Saha, Bibbuti; Majumdar, Vibek; Chattapadhya, Debasis; Saha, Kunal.
Título:Immunotherapy of lepromin-negative borderline leprosy patients with low-dose convit vaccine as an adjunct to multidrug therapy; a six-year follow-up study in Calcutta.
Fonte:Int. J. Lepr;65(1):56-62, Mar., 1997. tab.
Resumo:The present report, which describes management of lepromin-negative borderline leprosy patients with low-dose Convit vaccine, is an extension of our earlier study on the treatment of lepromatous leprosy patients with low-dose Convit vaccine as an adjunct to multidrug therapy (MDT). The test Group I, consisting of 50 lepromin-negative, borderline leprosy patients, were given low-dose Convit vaccine plus MDT. The control group II consisted of 25 lepromin-negative, borderline leprosy patients given BCG vaccination plus MDT and 25 lepromin-negative, borderline leprosy patients given killed Mycobacterium leprae (human) vaccine plus MDT. The control group III consisted of 50 lepromin-positive, borderline leprosy patients not given any immunostimulation but given only MDT. Depending upon the lepromin unresponsiveness, the patients were given one to four inoculations of the various antileprosy vaccines and were followed up every 3 months for 2 years for clinical, bacteriological and immunological outcome. All patients belonging to the test and control groups showed clinical cure and bacteriological negativity within 2 years. However, immunologic potentiation, assessed by lepromin testing and the leukocyte migration inhibition test (LMIT), was better in the test patients receiving low-dose Convit vaccine plus MDT than in the control patients receiving BCG vaccine plus MDT or killed M. leprae vaccine plus MDT or MDT alone. But the capacity of clearance bacteria (CCB) test from the lepromin granuloma showed poor bacterial clearance in the test patients. However, there was no relapse during 6 years of follow up. Two mid-borderline (BB) patients had severe reversal reactions with lagophthalmos and wrist drop during immunotherapy despite being given low-dose Convit vaccine. (AU)^ien.
Descritores:Hanseníase Dimorfa/quimioter
Hanseníase Dimorfa/terap
Mycobacterium leprae/imunol
Limites:Humanos
Masculino
Feminino
Localização:BR191.1


  4 / 48 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:27278
Autor:Carsalade, Georges-Yves de; Wallach, Daniel; Spindler, Edith; Pennec, Jean; Cottenot, Francois; Flageul, Beatrice.
Título:Daily multidrug therapy for leprosy; results of a fourteen-year experience.
Fonte:Int. J. Lepr;65(1):37-44, Mar., 1997. graf.
Resumo:Between 1980 and 1994, 67 new or relapsing leprosy patients were treated by daily administered multidrug regimens. Tuberculoid patients (23 TT/BT) received either bitherapy [rifampin + dapsone or clofazimine (RMP + DDS or CLO)] or tritherapy [RMP + DDS and/or CLO and/or ethionamide (ETH)] until clinical cure. Lepromatous patients (44 BB/BL/LL) received tritherapy (RMP + DDS and/or CLO and/or ETH) at least until bacteriological negativity. Of the 23 tuberculoid patients only one patient (5%) was cured at 6 months and about 70% needed between 6 and 24 months of treatment to obtain clinical cure (mean 19.5 months). In the 44 lepromatous patients, the achievement of bacteriological negativity was significantly linked to the initial bacterial index (BI), and it occurred after 2 to 7 years (mean 66.5 months) of multidrug therapy (MDT). The average BI decrease per year was 1.1+ during the first year, 0.9+ the second year, and then < 0.5+ per year. Reactional states significantly (p < 0.01) influenced the BI course: reversal reactions (RR) accelerated while erythema nodosum leprosum (ENL) delayed the BI decrease. Three of the 23 (13%) tuberculoid and 19 of the 44 (43%) lepromatous patients (p < 0.02) exhibited a RR and 18 of 44 (41%) lepromatous patients had ENL during MDT. A late RR (LRR) was observed in 1 (5%) and 6 (17%) of our tuberculoid and lepromatous patients, respectively, and 3 (8%) of our lepromatous patients suffered post-MDT ENL. No confirmed relapse has been observed within a follow-up period of 6 months to 7 years and 3 months [59 person-years at risk (PYR)] for TT/BT patients and of 4 months to 5 years and 10 months (100 PYR) for BB/BL/LL patients. When compared to the recommended WHO/MDT, it appears that daily MDT does not increase the clinical or the bacteriological cure rates either at 6 months in paucibacillary tuberculoid patients or at 2d years in multibacillary lepromatous patients. Moreover, as does the WHO/MDT, our regimens show a high frequency of reactional states both during and after treatment. This fact constitutes the main new problem of the actual treatment of leprosy. (AU)^ien.
Descritores:Hanseníase Dimorfa/quimioter
Hanseníase Virchowiana/quimioter
Hanseníase Tuberculóide/quimioter
Limites:Humanos
Masculino
Feminino
Localização:BR191.1


  5 / 48 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27235
Autor:Roche, Paul W; Theuvenet, Wim J; Le Master, Joseph W; Butlin, C. Ruth.
Título:Contribution of type 1 reactions to sensory and motor function loss in borderline leprosy patients and the efficacy of treatment with prednisone.
Fonte:Int. J. Lepr;66(3):340-347, Sept. 1998. tab.
Resumo:The changes in nerve function tests in 297 new leprosy patients over an average period of 30 months were measured. The impact of type 1 reactions (T1R) on sensory and voluntary muscle function was measured by standard tests. Sensory function was improved in patients with single episodes of cutaneous T1R, but not improved in patients with neural T1R or with multiple episodes of either kind of T1R. Patients over 40 years of age improved less than younger patients, and patients admitted for treatment of T1R improved more than those treated as outpatients. These data point to a need to find better regimens for the treatment of nerve damage in T1R. (AU)^ien.
Descritores:Hanseníase Dimorfa/quimioter
Hanseníase Dimorfa/fisiopatol
Neurônios Motores/fisiol
Neurônios Eferentes/fisiol
Prednisolona/uso terap
Limites:Humanos
Masculino
Feminino
Criança
Adolescente
Adulto
Idoso
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n3/v66n3a04.pdf - en.
Localização:BR191.1


  6 / 48 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27233
Autor:Rea, Thomas H; Sieling, Peter A.
Título:Delayed-type hypersensitivity reactions followed by erythema noodosum leprosum.
Fonte:Int. J. Lepr;66(3):316-327, Sept. 1998. tab.
Resumo:Reported herein are 13 borderline lepromatous (BL) or subpolar lepromatous (LLs) patients who presented with or developed delayed-type hypersensitivity (DTH) reactions after initiation of antibacterial therapy, but who subsequently developed erythema nodosum leprosum (ENL), the DTH to ENL group. During the same time, three LLs patients had ENL followed by relapse-associated DTH, a significant (p < 0.05) difference in sequence of the two conditions. The DTH to ENL group had statistically significant higher biopsy indexes at the time of diagnosis of the DTH reaction compared with two DTH control groups, 7 multibacillary patients presenting with DTH reactions and 15 BL or LLs who developed DTH reactions after starting treatment but had no ENL. DTH-associated histologic changes were less well developed in the DTH to ENL group than in either of the two control groups. In the DTH to ENL group, 77% required prednisone in addition to thalidomide to achieve a complete remission in contrast to only 10% of 21 ENL clinical controls. In the DTH to ENL group, the classical histologic ENL pattern was present in only 31% of these patients, in contrast to 88% of 33 ENL histologic controls. In 9 of 9 of the DTH to ENL patients studied, after the ENL remitted, Mycobacterium leprae-sonicate-stimulated lymphocyte transformation tests gave stimulation indexes within the range of our tuberculoid (TT) and borderline tuberculoid (BT) patients, in contrast to absent responses in 6 ordinary, longterm-treated patients who had had ENL. (AU)^ien.
Descritores:Hanseníase Dimorfa/quimioter
Hanseníase Dimorfa/imunol
Hanseníase Virchowiana/quimioter
Hanseníase Virchowiana/imunol
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n3/v66n3a02.pdf - en.
Localização:BR191.1


  7 / 48 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:25728
Autor:Anon
Título:Esquema uniforme de PQT para todos os casos de hanseniase: esboco do protocolo
Schedule of uniform MDT for all cases of leprosy: the draft protocol-
Fonte:s.l; s.n; 2002. 43 p. tab.
Descritores:Hanseníase Dimorfa/quimioter
Hanseníase Dimorfa/terap
Hanseníase Virchowiana/quimioter
Hanseníase Virchowiana/terap
Hanseníase Tuberculóide/quimioter
Hanseníase Tuberculóide/terap
Hanseníase/quimioter
Hanseníase/terap
Quimioterapia Combinada
Limites:Humanos
Masculino
Feminino
Localização:BR191.1; 01138/d.a


  8 / 48 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-pt
Id:23127
Autor:Ghidella, Cassio Cesar; Opromolla, Diltor Vladimir Araujo.
Título:Reacao tipo 1 pos alta / Type 1 reaction after the discharge
Fonte:Hansen. int;29(1):37-40, Jan.-Jun. 2004. ilus.
Resumo:E apresentado um caso de hanseniase pre-dimorfa tratada com PQT/PB/OMS com alguma melhora na ocasiao da alta. Um ano apos, a area de anestesia que apresentava no dorso do pe direito se estendeu pela panturrilha ate o cavo popliteo. Seis anos depois paciente retorna ao Centro de Saude com lesoes em placa quase planas roseo-hipocromicas anestesicas no tronco e pe esquerdo. Uma biopsia de uma lesao do abdome mostrou um quadro histopatologico compativel com reacao tipo 1 e baciloscopia igual a +++. Oa autores discutem a possibilidade dos bacilos estatem em um estado de persistencia e nao terem sido destruidos pelas drogas utilizadas. Segundo eles, apos a alta houve progressao dos bacilos pelos nervos determinando alteracoes no seu microambiente e consequentemente causando aumento da area anestesica sem serem reconhecidos ainda pelo sistema imune. Quando 6 anos depois eles se multiplicaram e foram finalmente reconhecidos pelas defesas do organismo, foram em parte destruidos, e deram lugar ao aparecimento de antigenos que desencadearam uma reacao de hipersensibilidade (reacao tipo 1). Os autores chamam a atencao que esses fatos tem que ser levados em consideracao no tratamento de pacientes nessas condicoes porque a resposta ao tratamento dos casos paucibacilares e diferente dos casos virchovianos (AU).
Descritores:HANSENIASE DIMORFA/clas
HANSENIASE DIMORFA/quimioter
HANSENIASE DIMORFA/imunol
HANSENIASE DIMORFA/patol
Limites:RELATO DE CASO
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/hansenint/v21aov29/2004/PDF/v29n1/v29n1a05.pdf - pt.
Localização:BR191.1


  9 / 48 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:22068
Autor:Rollier, M. R; Rollier, MM. M.
Título:Le traitment à long terme de la lèpre par la Sulfaméthoxypiridazine et la Dapsone.
Fonte:Acta Leprol;(55-56):11-19, Avril-Sépt. 1974. tab.
Descritores:HANSENIASE DIMORFA/quimioter
HANSENIASE VIRCHOWIANA/quimioter
HANSENIASE TUBERCULOIDE/quimioter
Localização:BR191.1


  10 / 48 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:20770
Autor:Shelleh, Hamdi H; Al-Shayeb, Abdul M; Khan, Sarosh A; Khan, Latif A; Al-Hateeti, Hussni S
Título:Cold cellulitis: an unusual presentation of leprosy
..-
Fonte:s.l; s.n; 2001. 2 p. ilus.
Resumo:The presentation of leprosy plays an important role in it´s identification. The features of the disease determine how it is clinically approached and diagnosed. Leprosy has diverse types of presentations. They are commonly calm and insidious.(AU).
Descritores:DOENCA AGUDA
BIOPSIA
CELULITE/diag
CELULITE/etiol
DIAGNOSTICO DIFERENCIAL
DERMATOSES FACIAIS/diag
DERMATOSES FACIAIS/etiol
INDIA/etnol
HANSENIASE DIMORFA/compl
HANSENIASE DIMORFA/diag
HANSENIASE DIMORFA/quimioter
HANSENIASE DIMORFA/etnol
DISTRIBUICAO ESPACIAL
Limites:RELATO DE CASO
HUMANO
MASCULINO
ADULTO
Meio Eletrônico: - .
Localização:BR191.1; 09105/s


  11 / 48 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:19103
Autor:Terencio de las Aguas, José; Chofré, Carmen; Contreras, Félix.
Título:Ineficacia terapéutica en un caso de lepra dimorfa.
Fonte:Fontilles - Revista de Leprología;21(5):593-601, May.-Ago. 1998. ilus.
Resumo:Se presenta el caso de una enferma de lepra dimorfa paucibacilar que depués de 10 años de multiterapia con seis drogas diferentes, no desaparecen las lesiones cutáneas y brotan algunas nuevas. Se sugiere realizar un tratamiento inmunoterápico. (AU).
Descritores:HANSENIASE
HANSENIASE DIMORFA/quimioter
Meio Eletrônico: - .
Localização:BR191.1


  12 / 48 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18974
Autor:Richard, B. M
Título:Location of the extracranial extent of leprous facial nerve pathology may allow leprous facial palsy to be reanimated by free muscle transfer
..-
Fonte:s.l; s.n; 2003. 7 p. ilus.
Resumo:Leprosy is a mycobacterial nerve and skin infection, which can be eradicated by antibiotics. Some patients affected by leprosy, once cured, have residual nerve impairment with paralysis and sensory neuropathy. A series of patients with facial nerve paralysis, investigated using clinical, histological and electrophysiological techniques, demonstrated that the nerve pathology was distal to the section of main trunk prior to its bifurcation. Facial reanimation was achieved with a free gracilis-muscle transfer, coapting its motor nerve to the ipsilateral facial nerve trunk proximal to the site of the leprosy pathology, with a moderate clinical result. (AU).
Descritores:PARALISIA FACIAL/microbiol
PARALISIA FACIAL/cirurg
ELETROMIOGRAFIA/métodos
HANSENIASE DIMORFA/compl
HANSENIASE DIMORFA/quimioter
HANSENIASE TUBERCULOIDE/compl
HANSENIASE TUBERCULOIDE/quimioter
COMPLICACOES POS-OPERATÓRIAS/etiol
RESULTADO DE TRATAMENTO
MUSCULO ESQUELETICO/transpl
Limites:RELATO DE CASO
HUMANO
MASCULINO
ADULTO
Meio Eletrônico: - .
Localização:BR191.1; 09089/s


  13 / 48 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:16347
Autor:Bourée, P; Brette, A. de; Carsalade, G. Y. de
Título:Réaction lépreuse tardive apparue 18 mois après la fin d'un traitement
Late reversal leprous reaction appearing 18 months after the termination of treatment-
Fonte:s.l; s.n; mars 2001. 1 p. .
Descritores:ANTIINFLAMATORIOS NAO ESTEROIDES
ANTIINFLAMATORIOS NAO ESTEROIDES
ANTIINFLAMATORIOS ESTEROIDES
ANTIINFLAMATORIOS ESTEROIDES
BIOPSIA
CLOFAZIMINA
CLOFAZIMINA
TINTURAS
SEGUIMENTOS
HIPERSENSIBILIDADE TARDIA
LEPROSTATICOS
LEPROSTATICOS
LEPROSTATICOS
HANSENIASE DIMORFA
HANSENIASE DIMORFA
HANSENIASE DIMORFA
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
PREDNISONA
PREDNISONA
PELE
FATORES DE TEMPO
Limites:RELATO DE CASO
Localização:BR191.1; 08684/s


  14 / 48 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15972
Autor:Flageul, B; Wagner, L; Cottenot, F
Título:Accidents immuno-allergiques à la rifampicine
..-
Fonte:s.l; s.n; 2002. 8 p. tab.
Descritores:HANSENIASE
HANSENIASE DIMORFA
HANSENIASE LEPROMATOSA
HANSENIASE TUBERCULOIDE
RIFAMPINA
RIFAMPINA
RIFAMPINA
RIFAMPINA
SULFONAMIDAS
SULFONAMIDAS
TROMBOCITOPENIA
TROMBOCITOPENIA
ANTIBIOTICOS COMBINADOS
CLOFAZIMINA
CLOFAZIMINA
DAPSONA
DAPSONA
HIPERSENSIBILIDADE A DROGAS
LEPROSTATICOS
LEPROSTATICOS
LEPROSTATICOS
Localização:BR191.1; 08568/s


  15 / 48 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15783
Autor:Sehgal, Virendra N; Kumar, Sunil; Jain, Sanjiv; Bhattacharya, Samit N
Título:Relapse (reactivation) in borderline tuberculoid (BT) leprosy
..-
Fonte:s.l; s.n; 1998. 2 p. ilus.
Descritores:HANSENIASE DIMORFA
HANSENIASE DIMORFA
HANSENIASE TUBERCULOIDE
HANSENIASE TUBERCULOIDE
LEPROSTATICOS
AGENTES ANTIINFECCIOSOS DE FLUOROQUINOLONA
ANTIBIOTICOS TETRACICLINICOS
DAPSONA
GRANULOMA
HISTIOCITOS
LINFOCITOS
MINOCICLINA
RECIDIVA
RIFAMPINA
Limites:ADULTO
HUMANO
MASCULINO
Localização:BR191.1; 07324/s


  16 / 48 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15646
Autor:Magdorf, K; Haas, W.H; Harns, P. H. Hoger; Griese, M; Rank, M
Título:Lepra-ein überblick aus pädiatrischer sicht
..-
Fonte:s.l; s.n; 2001. 5 p. tab.
Descritores:FATORES ETARIOS
CRIANÇA
DIAGNOSTICO DIFERENCIAL
LEPROSTATICOS
LEPROSTATICOS
HANSENIASE
HANSENIASE
HANSENIASE
HANSENIASE DIMORFA
HANSENIASE DIMORFA
HANSENIASE LEPROMATOSA
HANSENIASE LEPROMATOSA
HANSENIASE TUBERCULOIDE
HANSENIASE TUBERCULOIDE
FATORES DE TEMPO
VIAGEM
ORGANIZAÇAO MUNDIAL DA SAUDE
Limites:ESTUDO COMPARATIVO
Localização:BR191.1; 08422/s


  17 / 48 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15478
Autor:Archibald, Helen; Fitzpatrick, Peter F; Rée, G. Hugo
Título:Locally acquired Hansen's disease in North Queensland
..-
Fonte:s.l; s.n; jan. 1999. 2 p. ilus.
Descritores:BIOPSIA
DIAGNOSTICO DIFERENCIAL
FAMILIA
HANSENIASE DIMORFA
HANSENIASE DIMORFA
HANSENIASE DIMORFA
HANSENIASE DIMORFA
QUEENSLAND
DISTRIBUIÇAO ESPACIAL
FATORES DE RISCO
Limites:RELATO DE CASO
Localização:BR191.1; 08333/s


  18 / 48 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15466
Autor:Bourée, P; Brette, A. de; Carsalade, G. Y. de
Título:Réaction lépreuse tardive apparue 18 mois après la fin d'un traitement
Late reveral leprous reaction appearing 18 months after the termination of treatment-
Fonte:s.l; s.n; 2001. 1 p. .
Descritores:ANTIINFLAMATORIOS NAO ESTEROIDES
ANTIINFLAMATORIOS NAO ESTEROIDES
ANTIINFLAMATORIOS ESTEROIDES
ANTIINFLAMATORIOS ESTEROIDES
BIOPSIA
CLOFAZIMINA
CLOFAZIMINA
TINTURAS
SEGUIMENTOS
HIPERSENSIBILIDADE TARDIA
LEPROSTATICOS
LEPROSTATICOS
LEPROSTATICOS
HANSENIASE DIMORFA
HANSENIASE DIMORFA
HANSENIASE DIMORFA
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
PREDNISONA
PREDNISONA
PELE
FATORES DE TEMPO
Limites:RELATO DE CASO
Localização:BR191.1; 08321/s


  19 / 48 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15042
Autor:Zoprbas, P; Kontochristopoulos, G; Detsi, I; Apostolakis, E; Kouris, N; Katsambas, A
Título:Borderline tuberculoid leprosy coexisting with systemic lupus erythematosus
..-
Fonte:s.l; s.n; may 1999. 2 p. .
Descritores:AGENTES ANTIINFECCIOSOS DE FLUOROQUINOLONA
ANTIINFLAMATORIOS ESTEROIDES
CIPROFLOXACINA
ULCERA DO PÉ
ULCERA DO PÉ
HANSENIASE DIMORFA
HANSENIASE DIMORFA
HANSENIASE DIMORFA
LUPUS ERITEMATOSO SISTEMICO
LUPUS ERITEMATOSO SISTEMICO
LUPUS ERITEMATOSO SISTEMICO
PREDNISOLONA
Limites:RELATO DE CASO
Localização:BR191.1; 07489/s


  20 / 48 HANSEN  
              first record previous record
seleciona
para imprimir
Id:15035
Autor:Partida-Sanchez, S; Favila-Castillo, L; Pedraza-Sanchez, S; Gomez-Melgar, M; Saul, A; Estrada-Parra, S; Estrada-Garcia, I
Título:IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction in thalidomide treatment
..-
Fonte:s.l; s.n; 1998. 7 p. tab, graf.
Descritores:ADOLESCENCIA
ANTICORPOS ANTIBACTÉRIAS
ANTICORPOS ANTIBACTÉRIAS
INTERPRETAÇAO ESTATISTICA DE DADOS
ERITEMA NODOSO
INTERFERON TIPO II
INTERFERON TIPO II
LEPROSTATICOS
LEPROSTATICOS
LEPROSTATICOS
HANSENIASE DIMORFA
HANSENIASE DIMORFA
HANSENIASE TUBERCULOIDE
HANSENIASE TUBERCULOIDE
MYCOBACTERIUM LEPRAE
TALIDOMIDA
TALIDOMIDA
TALIDOMIDA
FATOR DE NECROSE TUMORAL/ME
IMUNOGLOBULINA M/BL/CL
FATOR DE NECROSE TUMORAL/*ME
Limites:ESTUDO COMPARATIVO
Localização:BR191.1; 07285/s



página 1 de 3 ir para página          
   


Refinar a pesquisa
  Base de dados : HANSEN Formulário avançado   
Pesquisar por : Formulário livre   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6.1 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information